50ampoules*2ml Laennec Placenta Japan Bio Laennec Inj Whitening Anti-Aging Repair Anti-Aging Beauty Remove

Product Description

Laennec placenta Anti-Aging Resist Melanin Whitening Skin Care Row Poison The Placenta

 

Laennec is a kind of moral medicine, which is manufactured with JBP's unique technology and can effectively extract various growth fact.ors, cytokines and other physiological active substances from human placenta. For example, HGF (hepatocyte growth fact.or) promotes the proliferation of liver parenchyma cells to restore the damaged liver.

The strictest safety measures in the existing scientific standards ensure the safety of our products.

 

Laennec (2ml*50amps) Human Placenta  Whitening Anti-Aging Repair

Laennec Placenta  

Placenta competitively inhibits melanin synthesis in the reaction of tyrosinase and L-DOPA by interrupting L-DOPA's ability to bind to tyrosinase during melanin synthesis. These results indicate that placenta inhibits the synthesis and agglutination of melanin by interrupting the function of L-DOPA.

 

Benefits of Laennec Human Placenta Whitening 50 оr 10 vials 2ml each - Sterile

- Placenta for Skin Whitening has Been Shown To Be Safe and Effective in Numerous Clinical Studies

- Laennec can cost $150 per vial at spas & clinics

- Contains 2ml of Sterile Human Placenta Which Has Been shown to Naturally Firm Whiten and Rejuvenate Skin

- Laennec by Japan Bio Products, Tokyo Japan is the Most Sought After Brand of Placenta

- Anti-Aging & cellular renewal

- Detoxifies and promotes cellular renewal

Description

This product is a light yellow-brown or yellow-brown clear liquid with a distinctive odor. The pH level ranges from 5.5 to 6.5 and the osmotic pressure ratio (to physiological saline) is approximately one.

 

Indications

Improvement of hepatic function in chronic hepatic disease.

 

Dosage and administration

The normal adult dose is a 2 ml subcutaneous or intramuscular injecion once daily. According to symptoms, the dose can be increased to 2 or 3 times daily.

 

Packaging

2 ml 50 ampoules

1. Careful Administration
LAENNEC should be administrated with care in patients predisposed to allergies.

2. Important Basic Cautions
This product is manufactured from the extract of human placenta delivered full-term in Japan. In order to screen each donor, a complete medical history, interviewing such as a history of travel and serologic testing for viruses, bacteria and infection are performed, after nucleic-acid testing (NAT) to meet with requirements for HBV-DNA, HCV-RNA and HIV-1-RNA is carried out. In addition, it has been confirmed that high-pressure steam sterilization for 20 minutes at 121 °C during the manufacturing process is effective in inactivating various viruses such as HIV etc. Furthermore, although in the product test, the nucleic-acid test meets with requirements for HBV-DNA, HCV-RNA, HIV-1-RNA, HTLV-DNA, and parvovirus B19-DNA, patients should be made aware of the following points during administration: To date, the transmission of infection, such as variant Creutzfeldt-Jakob disease (vCJD), by administration of this product in Japan or other countries has not been reported. However, although safety measures are taken to prevent infection during the manufacturing process, it is theoretically impossible to fully eliminate the risks of infection transmission originating in a human placenta used as raw material. While safety measures during the manufacturing process to prevent infection, as well as confirmation of the necessity of treatment for the disease before administration are carried out, doctors should explain to patients and try to have them understand that when human placenta is used as the raw material of a product, the risk of infection cannot be fully ruled out.

3. Drug Interactions

When this product is directly mixed with a strong base preparation of pH 8.5 or more, attenuation of pharmacological activity has been reported.No coadministration with this product resulting in the enhancement or attenuation of the pharmacological effect of this product or concomitant drugs, appearance of adverse reactions, or aggravation of disease has been reported.Adverse reactions or patients who were suspected to have suffered adverse reactions to this product were reported in a total of 10 (3.7 %) of the 273 patients selected for safety evaluation in the clinical study performed during implementation of reevaluation of the drug efficacy. The most frequently observed adverse reactions were injecion site pain in 7 patients (2.6 %), hypersensitivity (such as rash, fever, and itching) in 1 patient (0.4 %), injecion site indurations in 1 patient (0.4 %), and gynaecomastia in 1 patient (0.4 %). The cau sal relationship between gynaecomastia and this product is unknown.No abnormal changes in laboratory values were observed.1)• Clinically significant adverse reactions**Shock (incidence unknown):Since this product is a protein/amino acid preparation derived from human tissue, this product may cau se a shock. If any signs of abnormality are observed, the drug should be discontinued immediately, appropriate measures should be taken and the condition should be monitored fully.• Other adverse reactions (in descending order of occurrence)

 

product name

Laennec